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Abstract 
Background: Recent evidence indicates that inhibition of histone deacetylase (HDAC) protects the heart against 
myocardial injury and stimulates endogenous angiomyogenesis. However, it remains unknown whether HDAC inhibi-
tion produces the protective effect in the diabetic heart. We sought to determine whether HDAC inhibition preserves 
cardiac performance and suppresses cardiac remodeling in diabetic cardiomyopathy.
Methods: Adult ICR mice received an intraperitoneal injection of either streptozotocin (STZ, 200 mg/kg) to establish 
the diabetic model or vehicle to serve as control. Once hyperglycemia was confirmed, diabetic mice received sodium 
butyrate (1%), a specific HDAC inhibitor, in drinking water on a daily basis to inhibit HDAC activity. Mice were ran-
domly divided into following groups, which includes Control, Control + Sodium butyrate (NaBu), STZ and STZ + Sodium 
butyrate (NaBu), respectively. Myocardial function was serially assessed at 7, 14, 21 weeks following treatments.
Results: Echocardiography demonstrated that cardiac function was depressed in diabetic mice, but HDAC inhibition 
resulted in a significant functional improvement in STZ-injected mice. Likewise, HDAC inhibition attenuates cardiac 
hypertrophy, as evidenced by a reduced heart/tibia ratio and areas of cardiomyocytes, which is associated with 
reduced interstitial fibrosis and decreases in active caspase-3 and apoptotic stainings, but also increased angiogenesis 
in diabetic myocardium. Notably, glucose transporters (GLUT) 1 and 4 were up-regulated following HDAC inhibition, 
which was accompanied with increases of GLUT1 acetylation and p38 phosphorylation. Furthermore, myocardial 
superoxide dismutase, an important antioxidant, was elevated following HDAC inhibition in the diabetic mice.
Conclusion: HDAC inhibition plays a critical role in improving cardiac function and suppressing myocardial remod-
eling in diabetic heart.
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Background
Cardiovascular complications are the leading cause of 
diabetes-related morbidity and mortality worldwide [1]. 
Diabetes mellitus threatens to become a global health 
crisis; treatment of diabetes and its complications con-
stitutes a major health care expenditure. A significant 
proportion of diabetic patients are known to develop 
diabetic cardiomyopathy, with a high incidence of con-
gestive heart failure [2–4]. For example, in patients with 
diabetes mellitus, both the prevalence and severity of 
manifestations of coronary artery disease are increased 
compared with non-diabetic subjects. Experimental evi-
dence of diabetic cardiomyopathy has been accumulated 
in disease models with both type 1 and type 2 diabetes 
[5–8]. Evidence from STZ-induced hyperglycemia dis-
played decreased cardiac function, a reduction in cardiac 
mass over time, and a variety of morphological changes, 
including cardiac hypertrophy, myofibril depletion, inter-
stitial fibrosis, and microangiopathy [9–12].
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Histone acetyltransferases (HAT) and HDAC have 
recently garnered attention because they have emerged 
as important mechanisms in the regulation of a variety 
of cellular responses. Histone acetylation is mediated by 
HAT, which results in the modification of the structure of 
chromatin leading to nucleosomal relaxation, and altered 
transcriptional activation. In contrast, the reverse reac-
tion is mediated by HDACs which induce deacetylation, 
chromatin condensation, and transcriptional repression. 
The acetylation status of histone tails is determined by 
the interplay between HATs and HDACs [13–15]. Recent 
observation indicates that regulation of acetylation status 
mediates proteolytic function in diseased myocardium 
from human and animal models [16]. These recent stud-
ies have indicated the critical role of HDACs in modu-
lating myocardial ischemia/reperfusion injury, cardiac 
hypertrophy, and skeletal myogenesis [17–22]. Inhibition 
of HDACs using small molecules is regarded to be one 
of the most promising approaches for many pathological 
disorders.
Our studies have demonstrated that inhibition of 
HDACs plays a critical role in the prevention of myocar-
dial damages, mediation of cardiogenesis, and stimulation 
of myocardial repair [23–27]. In addition, the function of 
HDAC was reported to be associated with the pathologi-
cal process in diabetic status and/or heart failure [28, 29]. 
However, it remains unknown whether HDAC inhibition 
could produce a protective effect against myocardial dys-
function in diabetic mice. In this present study, we uti-
lized the STZ-induced diabetic model to define whether 
HDAC inhibition could preserve cardiac performance 
and attenuate cardiac remodeling.
Methods
Animals
Two-month old ICR male mice were purchased from 
Charles River Laboratories (Wilmington, MA, USA). All 
animal experiments were conducted under a protocol 
approved by the Institutional Animal Care and Use Com-
mittee of Institute, which conforms to the Guide for the 
Care and Use of Laboratory Animals published by the US 
National Institutes of Health (NIH Publication No. 85-23, 
revised 1996).
Experiment protocols
Two month-old mice were made diabetic by intraperi-
toneal injection of a single dose of freshly prepared STZ 
solution (200  mg/kg body wt dissolved in citrate buffer, 
pH 4.5) following overnight fasting [30]. Diabetic status 
was determined by measuring blood glucose concentra-
tion. Another group of mice was injected with vehicle 
(0.1  mol/l citrate buffer, pH 4.5) to serve as a control. 
Mice were randomly divided into four groups: Control 
group: mice only received an injection of vehicle (citrate 
buffer); Control  +  NaBu group: mice received sodium 
butyrate (1%), a specific HDAC inhibitor, in drinking 
water on a daily basis; STZ-treated group: mice received 
intraperitoneal injection of STZ; STZ  +  NaBu group: 
mice received intraperitoneal injection of STZ injection 
followed by sodium butyrate (1%), in drinking water on 
a daily basis. Tail vein blood glucose samples were meas-
ured using One Touch II Glucometer (Lifescan, Inc., Mil-
pitas, CA, USA) to confirm the induction of diabetes. All 
animals were euthanized at 21  weeks after injection of 
STZ.
Echocardiography
Echocardiographic parameters were accessed before and 
7, 14, and 21 weeks after the sodium butyrate treatments. 
Echocardiography was performed to evaluate left ven-
tricular (LV) functions using an Acuson Sequoia C512 
system (Siemens Helathcare, PA, USA) equipped with a 
15L8 linear array transducer. Mice were placed in supine 
position on a heating pad after being anesthetized with 
1.5% isoflurane mixed with oxygen. Pre-warmed ultra-
sound gel was applied on the chest throughout the meas-
urements. At the signal depth of 25 mm, 2-D B-mode and 
M-mode images were recorded on short axis views at the 
level of the papillary muscles. The following parameters 
were measured on the M-mode tracings and averaged 
from 3 to 6 cardiac cycles: left ventricular internal dimen-
sion-diastole (LVID;d), left ventricular internal dimen-
sion-systole (LVID;s), ejection fraction (EF), fraction 
shortening (FS), left ventricular posterior wall thickness 
in end-diastole (LVPW;d), and end-systole (LVPW;s). 
Data were calculated with accompanying software.
Immunohistochemistry
Tissue sections were de-paraffinized for 30 min at 70°C and 
subsequently immersed in xylene and ethanol at decreas-
ing concentration. Immunostaining was performed as 
described previously [27]. All de-paraffinized tissue sec-
tions went through antigen retrieval by boiling of slides 
at 100°C for 1 h. Wheat germ agglutinin (WGA) staining 
was carried out to measure cell size. The outline of myo-
cytes was traced in the LV of each animal, using NIH 
Image J software to determine myocyte cross-sectional 
area. A value from each heart was calculated by the meas-
urements of approximately 400–600 cells in a remote area 
from 5 randomly selected image areas in an individual 
heart. For evaluation of interstitial fibrosis, Picrosirius red 
staining of cardiac sections was conducted. Interstitial col-
lagen was examined from five randomly selected regions 
from each tissue section using an Olympus BX51 micro-
scope (Olympus, Center Valley, PA, USA). For α-smooth 
muscle actin (α-SMA) and cluster of differentiated CD31 
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immunostaining, cardiac sections were incubated with pri-
mary antibodies including CD31 (Millipore, Billerica, MA, 
USA) and anti-α-SMA (Sigma, St. Louis, MO, USA) over-
night at 4°C. Signals were visualized by incubation with the 
corresponding secondary antibodies including goat-anti-
rat-Cy3 and goat-anti-mouse-Cy3 (Life Technologies, 
Carlsbad, CA, USA) at room temperature for 1  h. Nuclei 
were stained with 4′, 6-diamidino-2-phenylindole (DAPI).
Terminal deoxynucleotidyl transferase dUTP nick end 
labeling (TUNEL) assay
De-paraffinized sections were processed for a TUNEL 
assay using a TACS® TdT In Situ Apoptosis Detection 
Kits (Trevigen, Gaithersburg, MD, USA) following the 
manufacturer’s instructions. TUNEL positive cells were 
observed using confocal laser scanning microscopy LSM 
700 (Carl Zeiss). The numbers of TUNEL positive cells 
were determined and were normalized to the tissue area. 
DAPI was used to counter stain for nuclei.
Immunoblotting and immunoprecipitation
Heart tissues were homogenized on ice in RIPA buffer 
with Halt protease and phosphatase inhibitor cocktail. 
Proteins (50 µg/lane) were resolved by SDS gel and trans-
ferred onto PVDF membranes. The membranes were 
then blocked with 5% powdered milk in TBST for 1 h and 
were subsequently probed with primary antibodies over-
night at 4°C. The following primary antibodies were used 
in this study: HDAC4, acetylated-Lysine, phosphorylated 
p38, and active casepase-3 from Cell Signaling (Danvers, 
MA, USA); GLUT 1, GLUT4, p38, SOD1, and β-actin 
were from Santa Cruz Biotechnology (Dallas, TX, USA). 
Horseradish peroxidase-conjugated monoclonal antibod-
ies (1: 2,000) were used for chemiluminescence detection.
For immunoprecipitation, samples were pre-cleared 
prior to immunoprecipitation to reduce the amount of 
non-specific contaminants. The EZView red protein A 
affinity gel (Sigma-Aldrich, St.Louis, MO, USA) was incu-
bated with myocardial lysates for 60 min at 4°C. Samples 
were centrifuged, and supernatants were obtained. Pro-
teins were incubated with the indicated primary anti-
bodies at 4°C overnight. Beads were added to lysate plus 
antibody mix, and proteins were further incubated for 2 h 
at 4°C. In addition, IgG was also used as immunoprecipi-
tation control and non-immunoprecipitated lysate was 
used as a control for detected molecular weight. After 
incubation, samples were washed with RIPA buffer five 
times, and proteins were eluted with 4× loading buffer by 
boiling and subjected to SDS-PAGE.
HDAC activity measurement
Myocardial HDAC activity was measured as described 
preciously in detail [25].
Statistical analysis
All data are expressed as mean  ±  SEM. Differences 
among multigroups were analyzed by one-way analysis of 
variance (ANOVA), followed by Bonferroni correction. A 




A single injection of STZ (200 mg/kg) was used to induce 
diabetes in ICR mice. At 1  week after the injection, the 
fasting blood glucose levels of >450 mg/dl were detected 
in all mice that received STZ injection. Approximately 
20% mice did not survive to sustain the toxicity of STZ 
by day 14. The surviving mice had blood glucose levels 
of >450 mg/dl throughout the study period. As shown in 
Fig. 1, sodium butyrate treatment did not lower the blood 
glucose level. The two diabetic groups showed no differ-
ence in blood glucose level by the end of the study period.
Ventricular function
Serial echocardiography was performed immediately 
before and up to 21 weeks after treatments. As shown 
in Fig. 2, STZ induced diabetic mice displayed cardiac 
dysfunction, as indicated by the reduction of both EF 
and FS as compared to Control group. However, admin-
istration of sodium butyrate resulted in improvements 
in EF and FS as compared with STZ group (Fig. 2a, b). 
The representative images of M-mode among groups 
are shown in Fig.  2c. Furthermore, an increase in left 
ventricular internal dimension (LVID) was observed 
in STZ-treated group as compared with Control and 
Fig. 1 The time course of measuring the concentration of blood glu-
cose. The peripheral blood concentration was measured on weekly 
basis. After overnight fasting, blood samples were collected from 
the tail tip vein on mice. Measurements were performed on control, 
STZ and STZ+ Sodium butyrate treatment groups, respectively. Mice 
with blood glucose readings of >250 mg/dl were diagnosed diabetic. 
Values represent mean ± SEM (n = 5–7 per group); CNTL control; STZ 
streptozotocin; NaB sodium butyrate.
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Control +  NaBu groups starting at 7  weeks following 
STZ injection throughout the 21-week period. LVID;s 
was significantly reduced in sodium butyrate-treated 
STZ mice as compared with STZ diabetic mice with-
out treatment (Additional file 1: Table S1). In addition, 
STZ-induced diabetic mice demonstrated an increase 
in LVPW, which was also attenuated by treatment 
of animals with sodium butyrate (Additional file  1: 
Table S1).
Cardiac remolding and interstitial collagen deposition
The ratio of heart weight to tibia length was used to 
evaluate the hypertrophic response. STZ injection 
resulted in an increase in the heart weight/tibia length 
ratio as compared to control hearts. Treatment of STZ 
mice with sodium butyrate significantly reduced the 
heart weight/tibia length ratio (Fig.  3a). In addition, 
STZ treatment caused a significant increase in heart 
weight/body weight ratios (Additional file 1: Table S2), 
which was prevented by treatment with sodium 
butyrate. STZ-induced diabetic mice WGA staining 
was performed to access the cross sectional cardio-
myocyte size. As shown in Figs. 3b, c, the STZ-treated 
mice showed an increase in cross-sectional cardiomyo-
cyte diameters as compared with control groups. How-
ever, the cross-sectional cardiomyocyte diameter was 
significantly reduced in STZ mice receiving sodium 
butyrate as compared with STZ mice only (Fig. 3c). As 
Fig. 2 Effects of HDAC inhibition on cardiac function in STZ-induced diabetic heart. Echocardiographic measurements of ventricular functional 
parameters includes: a Ejection fraction; b fractional shortening; c Representative echocardiographic M-mode images. Values are shown as 
mean ± SEM (n = 5–7 per group); *p < 0.05 vs STZ+ NaBu. NaBu sodium butyrate.
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shown in Fig.  4a, b, the collagen content was signifi-
cantly increased in STZ group as compared with con-
trol groups, but administration of sodium butyrate led 
to a reduction in interstitial collagen deposition in the 
myocardium as compared with STZ-treated mice alone 
although there is no statistically difference between the 
two diabetic groups.
Inhibition of HDACs resulted in up‑regulation of GLUT1 
and 4 and acetylation of GLUT1
When we measured HDAC activity in the diabetic myo-
cardium, HDAC activity demonstrated an increase in 
STZ-induced diabetic heart, but HDAC activity was sig-
nificantly reduced following the treatment of animals 
with sodium butyrate (Fig.  5a). In addition, as shown 
Fig. 3 Effects of HDAC inhibition on attenuating cardiac remodeling in STZ-induced diabetic heart. a The ratio of heart weight to tibia length. b 
Representative images of WGA staining in the MI hearts. c Quantitative analysis of myocyte cross-sectional area. Values are shown as mean ± SEM 
(n = 5 per group); *p < 0.05 vs CTRL, #p < 0.05 vs STZ+ NaBu. NaBu sodium butyrate. Scale bar 100 µm.
Fig. 4 Effect of HDAC inhibition attenuates interstitial collagen deposition in STZ-induced diabetic heart. a Representative images of histological 
picro-sirius red staining. b Quantitative analysis of myocyte interstitial collagen deposition. Values are shown as mean ± SEM (n = 5 per group); 
*p < 0.05 vs CTRL. NaBu sodium butyrate. Scale bar 100 µm
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Fig. 5 HDAC inhibition decreases HDAC activity and increases GLUT1 and GLUT4. a Measurement of HDAC activity in diabetic myocardium from 
different groups; b representative Western blot of HDAC4 proteins in myocardium; c densitometric analysis of Western blot of HDAC4 protein levels; 
d representative Western blot of GLUT4 proteins in myocardiums; e densitometric analysis of GLUT4 proteins in myocardium; f representative West-
ern blot of GLUT1 proteins in myocardium; g densitometric analysis of GLUT1 proteins in myocardium; h GLUT1 acetylation in diabetic myocardium. 
IB immunoblot; IP immunoprecipitation; IgG serves as IP control; lysates from myocardium serve as signal control of detected proteins. The densito-
metric signal was normalized to the control group and expressed as a percentage. Values are shown as mean ± SEM (n = 3 per group); *p < 0.05 vs 
CTRL, #p < 0.05 vs STZ+ NaBu. NaBu sodium butyrate.
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in Fig.  5b, c, treatment of mice with sodium butyrate 
decreased the expression level of HDAC4 in both Con-
trol and STZ-treated groups. Other HDAC isoforms 
were not changed in the diabetic myocardium between 
groups (Additional file 1: Figure. S1). The glucose trans-
porter signaling pathway was further confirmed. As 
shown in Fig.  5d–g, STZ induced a down-regulation of 
GLUT1 and GLUT4 protein levels in STZ heart as com-
pared with Control groups. However, HDAC inhibition 
resulted in up-regulations in both GLUT4 and GLUT1 in 
STZ heart, which restored the signal to the same level as 
the control group. Notably, GLUT1 was subjected to reg-
ulation by acetylation. As shown in Fig. 5h, HDAC inhibi-
tion increased the level of acetylated GLUT1 in sodium 
butyrate-treated STZ mice as compared with STZ alone. 
However, HDAC inhibition did not result in a signifi-
cant increase in acetylated GLUT4 although we noted 
there was a detectable level of acetylated GLUT4. Inter-
estingly, as shown in Fig.  6, we found that the diabetic 
myocardium demonstrated a decrease in phosphorylated 
p38 level, but HDAC inhibition resulted in a significant 
increase in phosphorylation of p38.
Anti‑apoptotic effects of HDAC inhibition in the diabetic 
myocardium
The apoptotic marker active caspase-3 was examined in 
the myocardium. As shown in Fig. 7a, active caspase-3 was 
increased in STZ group as compared with samples from 
Control groups. Densitometric analysis confirms that the 
administration of sodium butyrate significantly reduced acti-
vated caspase-3 in STZ mice (Fig. 7b). As shown in Fig. 7c, 
d, TUNEL analysis indicates that STZ-injection increased 
the number of TUNEL-positive nuclei, but HDAC inhibition 
reduced apoptotic signals in the diabetic heart.
HDAC inhibition increases endogenous antioxidant 
enzyme SOD1
Superoxide dismutase has been implicated in protective 
effects against myocardial ischemic injury. The levels of 
SOD1 in the myocardium were examined. As shown in 
Fig.  8a, all mice treated with sodium butyrate showed 
an increase in SOD1 level as compared to mice without 
sodium butyrate treatment. Densitometric analysis also 
indicates significant increases in SOD1 1evel follow-
ing HDAC inhibition (Fig.  8b). In addition, the diabetic 
myocardium demonstrated an increase in superoxide 
production, which was suppressed by HDAC inhibition 
(Additional file 1: Figure S2).
HDAC inhibition induces angiogenesis in the diabetic 
myocardium
As shown in Fig.  9a, CD31 positive capillary density 
was decreased in STZ mice. Administration of sodium 
butyrate substantially increased the capillary density in 
myocardium from STZ mice. Furthermore, we examined 
α-SMA positive microvessels in STZ-induced diabetic 
mouse hearts. Figure  9c shows α-SMA staining in the 
heart sections from all treatment groups. There is a sig-
nificant decrease in α-SMA-positive microvessels in STZ 
mice as compared to Control group, but HDAC inhibi-
tion resulted in a marked increase in microvessels. As 
shown in Fig.  9b, d, HDAC inhibition increased CD31 
and α-SMA positive vessels in the diabetic myocardium.
Discussion
Salient findings
Our study is the first to document that HDAC inhibi-
tion preserves cardiac performance and suppresses car-
diac remodeling in diabetic cardiomyopathy. Specifically, 
Fig. 6 HDAC inhibition increased p38 phosphorylation in diabetic myocardium. a Representative Western blot showing phosphorylated p38 and 
p38 proteins. b Densitometric analysis of phosphorylated p38 protein level in different groups. The densitometric signal was normalized to the 
control group and expressed as a percentage. Values are shown as mean ± SEM (n = 3 per group); *p < 0.05 vs CTRL, #p < 0.05 vs STZ+ NaBu. NaBu 
sodium butyrate.
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(1) Serial echocardiographic evaluation indicates that 
HDAC inhibition resulted in the preservation of ventric-
ular function in STZ-induced diabetic heart; (2) HDAC 
inhibition plays a profound effect in suppressing intersti-
tial fibrosis and attenuating myocyte hypertrophy in the 
diabetic myocardium; (3) HDAC inhibition mitigated the 
frequencies of apoptosis in the diabetic myocardium by 
decreasing active caspase 3 and TUNEL positive signals; 
(4) HDAC inhibition resulted in the increase of SOD1, 
GLUT1, and GLUT4 protein levels in diabetic hearts, 
Fig. 7 HDAC inhibition reduced apoptosis in STZ-induced diabetic heart. a Representative Western blots of active caspase-3. b densitometric 
analysis of active caspase-3 proteins. c Quantitative analysis of terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling 
(TUNEL)-positive nuclei in myocardium in different groups. d Representative images of TUNEL stainings in myocardial sections. Nuclei were stained 
in blue (DAPI) and cardiomyocytes in red (α-sarcomeric actinin); TUN EL-positive nuclei were stained in green. α-Sarc Act α-sarcomeric actinin; Values 
are shown as mean ± SEM (n = 3 per group for Western blots, n = 5 per group for TUNEL); *p < 0.05 vs CTRL, #p < 0.05 vs STZ+ NaBu. NaBu sodium 
butyrate. Scale bar 100 µm.
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Fig. 8 HDAC inhibition reduced SOD1 expression in myocardium. a Representative Western blots of active SOD1. b Densitometric analysis of West-
ern blot results. Values are shown as mean ± SEM (n = 3 per group); *p < 0.05 vs CTRL, #p < 0.05 vs STZ+ NaBu. NaBu sodium butyrate.
Fig. 9 HDAC inhibition promotes angiogenesis in STZ-induced diabetic heart. a, c Representative images of CD31 and α-SMA staining, respectively. 
b, d quantitative analysis of angiogenetic response. Results were indicated by the number of CD31- or α-SMA-positive cells per mm2. Values are 
shown as mean ± SEM (n = 3 per group); *p < 0.05 vs CTRL, #p < 0.05 vs STZ+ NaBu; NaBu sodium butyrate. Scale bar 100 µm for CD31, 200 µm for 
α-SMA.
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and acetylation of GLUT1 was elevated following HDAC 
inhibition; (5) Diabetic hearts exhibited significant 
decreases in CD31 and α-SMA positive microvessels, 
which was prevented following HDAC inhibition.
Recent evidence has indicated a genetic association 
between diabetes and HDACs. HDAC inhibitors promote 
β-cell development and function that positively affect 
diabetic microvascular complications [31]. Ventricular 
hypertrophy in diabetic hearts was mitigated by inhibi-
tion of HDACs [32]. Transient hyperglycemia is con-
sidered to promote gene-activating epigenetic changes 
critical in the progression of vascular complications [33]. 
Therefore, the function of epigenetics in the development 
of diabetes is largely recognized [34]. However, its impli-
cations in diabetes-associated cardiomyopathy remain 
to be determined. Our study showed that HDAC inhibi-
tion attenuates progressive dysfunction, suggesting that 
HDACs play an important role in controlling the pro-
gression of heart failure.
Clinical studies demonstrate that diabetes melli-
tus increased the susceptibility of the myocardium to 
ischemic injury [35, 36]. In the present study, when we 
employed a STZ-induced diabetic model [37], we have 
demonstrated that the diabetic myocardium (DM) pre-
sents with progressive LV systolic failure following STZ 
treatment for 21  weeks, which is consistent with obser-
vations in the development of cardiac dysfunction in 
STZ-induced diabetic rats [38]. This was supported by 
an observation that HDAC inhibition prevented the 
heart from effects of diet-induced obesity and insulin 
resistance in mouse models [39]. Further estimation of 
diastolic function in this model will determine whether 
diabetic cardiomyopathy developed. In addition, the low 
dose of STZ could be used as a diabetogenic method to 
induce diabetes to avoid the high rate of mortality caused 
by high dose of drug. Treatment of sodium butyrate also 
decreased HDAC activity and HDAC4 levels in DM myo-
cardium, which is in agreement with our recent obser-
vations that specific inhibition of HDAC4, by reducing 
HDAC4 protein, promotes stem cell-derived myocardial 
repair [40]. Furthermore, we could not find significant 
changes in other HDAC isoforms following HDAC inhi-
bition in diabetic myocardium. Myocardial enhancing 
factor 2 (MEF2) is reported to be associated with class II 
HDACs to mediate cardiac growth and remodeling [41]. 
We found that HDAC inhibition only slightly increased 
MEF2 protein levels in STZ-induced myocardium (not 
shown), implying that MEF2 may not be a major target 
following HDAC inhibition in STZ-induced diabetic 
myocardium. An important pathological feature of dia-
betic cardiomyopathy is cardiac hypertrophy [42]. In the 
initial stage, this hypertrophic cardiomyopathy may be 
an adaptive response responsible for enhancing cardiac 
performance [43]. However, sustained hypertrophic 
growth of the myocardium may be associated with the 
occurrence of myocardial remodeling [20]. HDAC inhibi-
tors blocked cardiac hypertrophy induced by angiotensin 
II infusion and aortic banding (18.19). We observed that 
HDAC inhibition remarkably prevented these hyper-
trophic features in DM. The anti-hypertrophic effect 
of HDAC inhibition in the DM heart is well mirrored 
by our recent studies in which cardiac hypertrophy was 
mitigated in the infarcted hearts following global HDAC 
inhibition or infarcted hearts engrafted with cardiac stem 
cells treated with HDAC inhibitors [27].
Myocardial fibrosis is another important hallmark of 
diabetic cardiomyopathy, and it is also featured by the 
accumulation of interstitial collagens in the hearts [44]. 
The present results demonstrate that interstitial collagen 
in DM hearts was reduced after treatment with HDAC 
inhibition, indicating the function of HDAC in preventing 
interstitial fibrosis. Another finding is an increase of myo-
cyte apoptosis in DM hearts. Although the significance 
of myocyte apoptosis in diabetic myocardium remains 
speculative, progressive loss of myocytes could exacerbate 
cardiac dysfunction and structure deterioration.
We reported that HDAC inhibition protects the heart 
against ischemia/reperfusion through blocking of reac-
tive oxidant species [25]. Oxidative stress has been 
suggested by several studies to underlie hyperglycemia-
induced myocardial cell deaths [45–47]. High glucose-
induced cardiomyocyte apoptosis is associated with the 
generation of reactive oxygen species [48], and normali-
zation of SOD1 activity was associated with consequent 
bolstering of anti-oxidant defenses in diabetes [49].The 
present study shows that SOD1 was markedly increased 
by HDAC inhibition, suggesting that the increased anti-
oxidant stress elicited by HDAC inhibition accounts for 
the suppression of myocardial remodeling in the diabetic 
heart. In addition, the production of superoxides was 
increased in the diabetic myocardium, but HDAC inhi-
bition attenuated the superoxide production of diabetic 
hearts, revealing a link between HDAC inhibition and 
suppression of superoxide.
It is known that pathological cardiac hypertrophy 
with reduced contractility is accompanied by impaired 
coronary angiogenesis [50]. The reductions in capillary 
and arteriolar densities were shown in the myocardial 
infarction model of diabetic conditions [51, 52]. Our 
study demonstrates a significant reduction in microves-
sel density in diabetic myocardium, but vascular growth 
was stimulated by treatment with HDAC inhibition. This 
increase in microvessel density following HDAC inhibi-
tion in diabetic myocardium may also be attributable to 
the improvement in cardiac function and attenuation of 
remodeling.
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Two glucose transporter proteins (GLUT1 and GLUT4) 
were reported to be reduced in the diabetic myocardium 
[53]. We have shown that GLP-1-induced myocardial 
protection is associated with the increase of GLUT4 [53]. 
In this study, both GLUT1 and GLUT4 were decreased 
in the diabetic myocardium, but the decrease of both 
GLUT1 and GLUT4 was prevented by HDAC inhibi-
tion. Interestingly, our results show that acetylation of 
GLUT1 was increased by HDAC inhibition. However, 
HDAC inhibition did not result in a significant change 
in the acetylation of GLUT4 (data not shown). This sug-
gests that acetylation of GLUT1 and GLUT4 may respond 
differently following HDAC inhibitions or depend on the 
magnitudes of HDAC inhibition. Although the content 
of GLUT1 and GLUT4 were increased by HDAC inhibi-
tion in the diabetic animals, blood glucose level was not 
reduced by HDAC inhibition in this studies. It is likely 
that HDAC inhibition could not reduce the peripheral 
glucose concentration, but instead modulate insulin 
resistance in the diabetic status, which will be an interest-
ing subject to investigate in the future. It is interesting to 
elucidate whether acetylation of GLUT1 could mediate 
its physiological functions in the future. In addition, we 
have shown that p38 phosphorylation was associated with 
cardioprotection induced by glucagon-like peptide (GLP-
1) in myocardial ischemia and reperfusion [54]. The pre-
sent study again reveals that HDAC inhibition increased 
p38 phosphorylation in diabetic hearts. The future study 
may attempt to document whether there exists a direct 
relationship between p38 phosphorylation and GLUT1 
acetylation in diabetic hearts. It is not clear whether the 
PI3 kinase/Akt-1 signaling pathway is also involved in 
the protective effects induced by HDAC inhibition. On 
the other hand, mitochondrial oxygen consumption was 
impaired in the diabetes related mouse model [55].Our 
previous observation also indicates that stimulation of 
GLP-1R could increase mitochondrial oxygen consump-
tion in myoblasts exposed to hypoxia/reoxygenation [56]. 
It is not clear whether HDAC inhibition could also modu-
late mitochondrial oxygen consumptions in this observa-
tion. It has been reported that pathological stress activates 
the chromatin repressor complex containing HDAC to 
inhibit the transcription of Mhrt, a long noncoding RNA 
in the heart [57]. It would be interesting to define whether 
long non-coding transcripts would also involve the pro-
tective effects of HDAC inhibitors in the prevention of 
diabetic pathology. In this study, we utilized a high dose 
of STZ to induce the diabetic model. Because the dose of 
STZ that was used could be cytotoxic in the animal strain, 
this could be associated with the high mortality rate and 
abundant myocyte death during the development of dia-
betes. This could complicate the type 1 diabetic pheno-
type. This is a limitation for this observation.
Conclusion
Our study is the first to document that HDAC inhibition 
attenuated diabetic cardiomyopathy by improving ven-
tricular function, attenuating remodeling, and suppress-
ing cardiac hypertrophy. The protective effects of HDAC 
inhibition in the diabetic myocardium are closely asso-
ciated with decreased apoptosis, stimulation of endog-
enous angiogenesis, an increase of anti-oxidant SOD1, 
and activations of GLUT1 acetylation and p38 phospho-
rylation. HDAC inhibition provides a novel approach to 
the treatment of patients with diabetic cardiomyopathy. 
Our study indicated that inhibition of HDACs effectively 
prevented cardiac dysfunction and cardiac remodeling 
in the diabetic heart, which is related to the promo-
tion of angiogenesis, anti-apoptosis, and acetylation of 
GLUT1.
Perspectives and translational implication
Diabetes mellitus threatens to become a global health cri-
sis; treatment of diabetes and its implications constitutes 
a major health care expenditure. A significant proportion 
of diabetic patients are known to develop diabetic cardio-
myopathy, which is one of the leading causes of increased 
morbidity and mortality in patients with diabetes mel-
litus. HDAC regulates transcriptional changes and plays 
a critical role in mediating myocardial development and 
disease. From both a mechanistic and a translational 
point of view, the pathway identified in the present study 
will provide a strong foundation on which HDAC inhibi-
tion may serve as the novel therapeutic target to prevent 
the progression of diabetes-induced cardiac dysfunc-
tion. HDAC inhibitors are well tolerated in humans, and 
clinical trials investigating their efficacy in anti-cancer 
therapy are currently underway. Therefore, the thera-
peutic merit of HDAC inhibition in treating diabetic car-
diomyopathy is potentially important. Exploration of the 
functional role of HDAC inhibition and evaluation of its 
clinical outcome will provide direct evidence to support a 
potential clinical implication.
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